SNT - Research & Valuation

Constellation pharma had a Bromodomain and Extra-Terminal (BET) protein inhibitor called Pelabresib for MF and MDS.

Morphosys acquired Constellation for $1.7Bn in June 2021.

https://www.morphosys.com/en/news/morphosys-acquire-constellation-pharmaceuticals

Next Novartis acquired Morphosys in Feb 2024 for US $2.92 Bn (EUR $2.7 Bn)

https://www.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash

The focus of these acquisitions is the combined MF and MDS trial being trialled in combination with JAK inhibitor (Ruxolitinib)- https://clinicaltrials.gov/study/NCT02158858

No.of patients: 336

In the 1/7/24 preso slide 11, Gary has this transaction as successful phase 3- details of the trials here- https://clinicaltrials.gov/study/NCT04603495

Syntara SNT-5505 in MF: https://clinicaltrials.gov/study/NCT04676529

We are also doing a combination trial with the JAK inhibitor ruxolitinib

No.of patients: 39

From the looks of it, Constellation’s and Syntara’s MF trials have similar endpoints (at a high level) although vastly different patient populations.

So yes, at the December readout we may be in the crosshairs of some BPs.

AIMO. DYOR.